Elanco CFO awarded deferred stock units

Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities.

Rhea-AI Filing Summary

Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities. On January 23, 2026, he acquired 7.8029 deferred stock units at a reference price of $24.4 per unit.

Following this transaction, he beneficially owned 15.915 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.

Insider Trade Summary

Grant/Award: 7.8029 shares

Grant/Award 1 txn

Insider VanHimbergen Robert M

Role EVP and CFO

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	7.8029	$24.40	$190.39

Holdings After Transaction: Deferred Stock Units — 15.915 contracts (Direct)

Footnotes (2)

1. F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
2. F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ELAN report for its CFO on January 23, 2026?

Elanco (ELAN) reported its EVP and CFO acquiring deferred stock units. On January 23, 2026, Robert M. VanHimbergen acquired 7.8029 deferred stock units at a reference price of $24.4, increasing his directly held deferred stock units to 15.915.

What are the deferred stock units reported in the ELAN Form 4 filing?

The deferred stock units give a right to future Elanco value. Each unit represents the right to receive one share of Elanco common stock or its cash equivalent, providing equity-linked compensation rather than immediate share ownership for the executive.

How many deferred stock units does the Elanco (ELAN) CFO hold after this transaction?

After the reported transaction, the CFO beneficially owns 15.915 deferred stock units. This total reflects the addition of 7.8029 newly acquired units and represents his directly held derivative position tied to Elanco common stock.

At what price were the Elanco (ELAN) deferred stock units credited in this Form 4?

The newly acquired deferred stock units were credited at $24.4 per unit. This price is the reference amount used for the 7.8029 units reported, linking the deferred compensation value to Elanco’s common stock at that level.

When will the Elanco (ELAN) CFO’s deferred stock units settle?

The deferred stock units settle after employment ends or in a specified future year. Settlement occurs in cash or shares of Elanco common stock under the company’s Executive Deferral and Stock Match Plan, aligning compensation timing with long-term service.

Is the Elanco (ELAN) CFO’s deferred stock unit holding direct or indirect?

The Form 4 shows the deferred stock units as directly owned. The ownership form is reported as “D” (Direct), with no indicated indirect holding entity or footnote disclaiming voting or investment authority over these derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:27 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	01/23/2026		A		7.8029		(2)	(2)	Common Stock	7.8029	$24.4	15.915	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.